BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2308919)

  • 21. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer.
    Siitonen SM; Kallioniemi OP; Isola JJ
    Am J Pathol; 1993 Apr; 142(4):1081-9. PubMed ID: 7682759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
    Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical assessment of proliferation rate of breast carcinoma cells using Ki-67, MIB-1 and anti-PCNA monoclonal antibodies.
    Markiewski M; Domagała W
    Pol J Pathol; 1996; 47(4):189-94. PubMed ID: 9097711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen and progesterone receptors in breast cancer: comparison between enzyme immunoassay and computer-assisted image analysis of immunocytochemical assay.
    Cavaliere A; Bucciarelli E; Sidoni A; Bianchi G; Pietropaoli N; Ludovini V; Vitali R
    Cytometry; 1996 Sep; 26(3):204-8. PubMed ID: 8889392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
    Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
    Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
    Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F
    Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters.
    Thike AA; Chng MJ; Fook-Chong S; Tan PH
    Pathology; 2001 Feb; 33(1):21-5. PubMed ID: 11280603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
    Cheang MC; Treaba DO; Speers CH; Olivotto IA; Bajdik CD; Chia SK; Goldstein LC; Gelmon KA; Huntsman D; Gilks CB; Nielsen TO; Gown AM
    J Clin Oncol; 2006 Dec; 24(36):5637-44. PubMed ID: 17116944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
    Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
    Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [In situ determination of the Ki-67 growth fraction (Ki-67 GF) in human tumors (studies in breast cancer)].
    Lellé RJ
    Acta Histochem Suppl; 1990; 39():109-24. PubMed ID: 2080254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen and progesterone receptor expression and proliferation in breast cancer cells, studied with flow cytometry.
    Scheres HM; Schutte B; De Goij AF; Bosman FT
    Acta Histochem Suppl; 1990; 40():71-6. PubMed ID: 2091049
    [No Abstract]   [Full Text] [Related]  

  • 36. [Immunocytochemical evaluation of estrogen receptors in histological specimens of primary breast cancer].
    Gorczyca W; Olszewski W; Woyke S; Chrapusta S; Konopka B; Paszko Z
    Patol Pol; 1990; 41(1-2):58-66. PubMed ID: 2100791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic values of proliferative markers ki-67 and repp86 in breast cancer.
    Mohsenifar J; Almassi-Aghdam M; Mohammad-Taheri Z; Zare K; Jafari B; Atri M; Mortazavi SH; Azadeh P; Bagherzadeh M; Azargashb E; Rahimi F
    Arch Iran Med; 2007 Jan; 10(1):27-31. PubMed ID: 17198450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunocytochemical detection of progesterone receptor by monoclonal KD-68 antibody in operable breast cancer: correlations with biochemical assay, pathological features and cell proliferative rate.
    Bevilacqua P; Pea M; Gasparini G
    Eur J Cancer Clin Oncol; 1989 Nov; 25(11):1595-602. PubMed ID: 2687004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival.
    Locker AP; Birrell K; Bell JA; Nicholson RI; Elston CW; Blamey RW; Ellis IO
    Eur J Surg Oncol; 1992 Jun; 18(3):224-9. PubMed ID: 1607032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical demonstration of cell proliferation and estrogen receptor status in human breast cancer. Analysis of 45 cases.
    Hori M; Furusato M; Nikaidoh T; Aizawa S
    Acta Pathol Jpn; 1990 Dec; 40(12):902-7. PubMed ID: 1965755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.